We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
Cap. Flow
-$10.2M
Cap. Flow %
-0.22%
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$54.7M
2
EAR
Eargo, Inc. Common Stock
EAR
+$37.9M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$37.2M
4
SPRB
Spruce Biosciences
SPRB
+$36M
5
LUNG icon
Pulmonx
LUNG
+$24.5M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$135M
2
CNC icon
Centene
CNC
+$37.5M
3
BAX icon
Baxter International
BAX
+$27.2M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.1M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 92.97%
2 Consumer Staples 1.52%
3 Consumer Discretionary 0.76%
4 Industrials 0.46%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
101
Spyre Therapeutics
SYRE
$8.9B
$12.4M 0.26%
63,200
-421
-0.7% -$87.3K
FPRX
102
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$12.3M 0.26%
721,633
+450,048
+166% +$5.64M
TBPH icon
103
Theravance Biopharma
TBPH
$877M
$12.1M 0.26%
678,200
-145,818
-18% -$2.62M
TBIO
104
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$11.9M 0.25%
643,500
+854
+0.1% +$15.3K
KYNB
105
Kyntra Bio
KYNB
$28.9M
$11.5M 0.24%
12,375
+4
+0% +$4.21K
FUSN
106
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$11.1M 0.24%
948,327
+786
+0.1% +$9.87K
NGM
107
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$10.9M 0.23%
360,500
+46
+0% +$1.01K
TXG icon
108
10x Genomics
TXG
$7.72B
$10.8M 0.23%
76,000
– –
AUPH icon
109
Aurinia Pharmaceuticals
AUPH
$2.06B
$10.7M 0.23%
773,669
+1,100
+0.1% +$16K
KDNY
110
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$10.6M 0.22%
+668,849
New +$10.1M
PRTK
111
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.5M 0.22%
1,680,614
+7,200
+0.4% +$42.4K
CHMA
112
DELISTED
Chiasma, Inc. Common Stock
CHMA
$9.29M 0.2%
2,136,514
-7,711
-0.4% -$32.1K
TRIL
113
DELISTED
Trillium Therapeutics Inc.
TRIL
$9.1M 0.19%
618,500
-152,418
-20% -$2.2M
SRRA
114
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$9.1M 0.19%
+567,358
New +$7.88M
CNMD icon
115
CONMED
CNMD
$1.5B
$8.74M 0.19%
78,000
-102,000
-57% -$9.66M
LEGN icon
116
Legend Biotech
LEGN
$4.19B
$8.71M 0.18%
309,418
+57,280
+23% +$1.65M
NRIX icon
117
Nurix Therapeutics
NRIX
$2.7B
$8.46M 0.18%
257,250
-264
-0.1% -$8.75K
ADAP
118
DELISTED
Adaptimmune Therapeutics
ADAP
$8.33M 0.18%
1,545,000
-441,910
-22% -$2.4M
WST icon
119
West Pharmaceutical
WST
$24.7B
$8.07M 0.17%
28,500
– –
ELVN icon
120
Enliven Therapeutics
ELVN
$4.26B
$7.95M 0.17%
90,125
+389
+0.4% +$32.6K
XENE icon
121
Xenon Pharmaceuticals
XENE
$6.18B
$7.92M 0.17%
515,000
-711
-0.1% -$8.32K
QURE icon
122
uniQure
QURE
$3.11B
$7.53M 0.16%
208,500
-204,933
-50% -$8.64M
DVAX
123
DELISTED
Dynavax Technologies
DVAX
$7.34M 0.16%
1,649,420
+1,500
+0.1% +$6.79K
BCEL
124
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.29M 0.15%
451,230
+400
+0.1% +$6K
ODT
125
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$7.25M 0.15%
377,700
-111,732
-23% -$1.72M
3 4
5
6 7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
  • Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
  • Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
  • Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
  • Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.